ACET

Healthcare Biotechnology

Adicet Bio, Inc.

$6.50

-0.14 -2.11% today

Price History

Not enough data

Key Stats

Market Cap

60.85M

Avg Volume

162,614

EPS

-$10.42

52W High

$17.44

52W Low

$6.01

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-1.61

P/B Ratio

0.58

EV/EBITDA

0.36

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(78.1%)

Return on Assets

(41.7%)

Liquidity & Leverage

Current Ratio

6.71

Quick Ratio

6.59

Debt / Equity

0.11

Total Cash

118.19M

Total Debt

12.85M

About

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.